Does Vildagliptin 100 SR Cause Mouth Ulcers?
Vildagliptin 100 mg sustained-release does not appear to cause mouth ulcers based on available safety data, though rare mucosal reactions cannot be entirely excluded.
Evidence Analysis
The most comprehensive safety evaluation of vildagliptin 100 mg SR comes from a prospective post-marketing surveillance study of 210 patients over 24 weeks 1. This study reported only 9 adverse drug reactions in 7 patients (3.3% incidence), all of which were mild, non-serious events—with no mention of oral ulcers or mouth lesions among the reported adverse effects.
A larger European multidatabase study examining 738,054 patients (2.8% on vildagliptin) specifically evaluated skin lesions as a safety outcome 2. The adjusted incidence rate ratios for skin lesions ranged from 0.37-1.18, with confidence intervals not exceeding 1, indicating no increased risk of skin or mucosal lesions compared to other non-insulin antidiabetic drugs.
Important Distinction: DPP-4 Inhibitors and Mucosal Effects
While the evidence provided discusses EGFR-TKI inhibitors causing aphthous ulcerations of oral and nasal mucosa 3, this is irrelevant to vildagliptin, which is a DPP-4 inhibitor with an entirely different mechanism of action. These are distinct drug classes with different adverse effect profiles.
Research on alogliptin (another DPP-4 inhibitor) showed delayed healing of traumatic oral ulcers in animal models 4, but this addresses ulcer healing rather than ulcer causation, and extrapolation from animal trauma models to human spontaneous ulceration is not clinically appropriate.
Clinical Caveat: Bullous Pemphigoid
One notable exception exists: Three case reports documented vildagliptin-associated bullous pemphigoid (BP) in elderly diabetic patients 5. BP presents with blistering lesions that can affect mucous membranes, though it primarily manifests as skin blisters rather than typical oral ulcers. Symptoms completely resolved after vildagliptin discontinuation, establishing a probable causal relationship in these cases.
Key Distinguishing Features:
- BP presents with tense bullae (fluid-filled blisters), not aphthous-type ulcers
- Primarily affects skin with possible mucosal involvement
- Occurs in elderly patients
- Requires direct immunofluorescence for diagnosis
- Resolves with drug discontinuation
Clinical Recommendation
If a patient on vildagliptin 100 SR develops mouth ulcers:
Evaluate the ulcer characteristics: Typical aphthous ulcers (well-demarcated, oval/round with white/yellow pseudomembrane and erythematous halo) are unlikely related to vildagliptin 6
Consider alternative causes: Trauma, nutritional deficiencies, autoimmune conditions, or other medications are more probable etiologies
If blistering lesions develop (not typical ulcers), consider drug-induced bullous pemphigoid, particularly in elderly patients—discontinue vildagliptin and refer for dermatologic evaluation
For persistent ulcers >2 weeks: Perform biopsy and comprehensive workup per standard oral ulcer guidelines 6, but vildagliptin discontinuation is not routinely indicated based on current evidence
The overall safety profile demonstrates vildagliptin 100 mg SR is well-tolerated with minimal mucosal adverse effects in real-world use 1, 7.